Cargando…

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients

The therapeutic goal for hepatitis B virus (HBV) infection is HBs antigen (HBsAg) seroclearance, which is achieved through 48-week pegylated interferon (Peg-IFN) therapy. This study aimed to identify predictive biomarkers for sustained HBsAg reduction by analyzing serum microRNAs. Twenty-two consecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujita, Koji, Mimura, Shima, Iwama, Hisakazu, Nakahara, Mai, Oura, Kyoko, Tadokoro, Tomoko, Nomura, Takako, Tani, Joji, Yoneyama, Hirohito, Morishita, Asahiro, Oryu, Makoto, Himoto, Takashi, Nishitsuji, Hironori, Shimotohno, Kunitada, Omata, Masao, Masaki, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073286/ https://www.ncbi.nlm.nih.gov/pubmed/30004437 http://dx.doi.org/10.3390/ijms19071940

Ejemplares similares

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir
por: Morishita, Asahiro, et al.
Publicado: (2018)

Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up
por: Tadokoro, Tomoko, et al.
Publicado: (2021)

Galectin-9 ameliorates fulminant liver injury
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Cancer Therapy Due to Apoptosis: Galectin-9
por: Fujita, Koji, et al.
Publicado: (2017)

Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022)

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022)

Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis
por: Shi, Tingting, et al.
Publicado: (2020)

Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020)

Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs
por: Fujita, Koji, et al.
Publicado: (2016)

MicroRNA profiles in various hepatocellular carcinoma cell lines
por: Morishita, Asahiro, et al.
Publicado: (2016)

Association between microRNA-527 and glypican-3 in hepatocellular carcinoma
por: Nomura, Kei, et al.
Publicado: (2021)

Albumin–bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C
por: Fujita, Koji, et al.
Publicado: (2019)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
por: Morishita, Asahiro, et al.
Publicado: (2021)

Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest
por: Samukawa, Eri, et al.
Publicado: (2017)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Characteristic waffle-like appearance of gastric linitis plastica: A case report
por: MAEDA, EMIKO, et al.
Publicado: (2015)

Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection
por: Fujita, Koji, et al.
Publicado: (2018)

Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study
por: Tani, Joji, et al.
Publicado: (2021)

Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen
por: Washizaki, Ayaka, et al.
Publicado: (2022)

Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature
por: Oura, Kyoko, et al.
Publicado: (2021)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease
por: Himoto, Takashi, et al.
Publicado: (2017)

Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion
por: Nomura, Takako, et al.
Publicado: (2019)

Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study
por: Tani, Joji, et al.
Publicado: (2020)

Submucosal tunneling techniques: current perspectives
por: Kobara, Hideki, et al.
Publicado: (2014)

Albumin–Bilirubin Score Differentiates Liver Fibrosis Stage and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Virus Infection: A Retrospective Cohort Study
por: Fujita, Koji, et al.
Publicado: (2019)

Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest
por: Oura, Kyoko, et al.
Publicado: (2017)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

MicroRNA profile of hepatic epithelioid hemangioendothelioma: A case report
por: Morishita, Asahiro, et al.
Publicado: (2017)

Nutritional Support for Alcoholic Liver Disease
por: Tadokoro, Tomoko, et al.
Publicado: (2023)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

MicroRNA Interference in Hepatic Host-Pathogen Interactions
por: Morishita, Asahiro, et al.
Publicado: (2021)

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review
por: Morishita, Asahiro, et al.
Publicado: (2021)

Giant cutaneous metastasis from hepatocellular carcinoma
por: Morishita, Asahiro, et al.
Publicado: (2022)

The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKa/mTOR pathway in vitro and in vivo
por: Fujihara, Shintaro, et al.
Publicado: (2016)

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy
por: Oura, Kyoko, et al.
Publicado: (2023)

MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis
por: KATSURA, AKIKO, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e9l9nna4cbehn9espcj68rjbvf